Auspex Pharmaceuticals (NASDAQ: ASPX) is one of 291 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Auspex Pharmaceuticals to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Auspex Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auspex Pharmaceuticals 0 0 0 0 N/A
Auspex Pharmaceuticals Competitors 1176 3523 12063 248 2.67

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.48%. Given Auspex Pharmaceuticals’ rivals higher possible upside, analysts plainly believe Auspex Pharmaceuticals has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

49.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Auspex Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auspex Pharmaceuticals N/A -61.66% -50.55%
Auspex Pharmaceuticals Competitors -5,345.53% -158.67% -35.84%

Valuation & Earnings

This table compares Auspex Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Auspex Pharmaceuticals N/A N/A -36.85
Auspex Pharmaceuticals Competitors $290.27 million $35.99 million 68.43

Auspex Pharmaceuticals’ rivals have higher revenue and earnings than Auspex Pharmaceuticals. Auspex Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Auspex Pharmaceuticals rivals beat Auspex Pharmaceuticals on 6 of the 8 factors compared.

About Auspex Pharmaceuticals

Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.

Receive News & Ratings for Auspex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auspex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.